好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Incidence of Spreading Depolarizations in Severe Traumatic Brain Injury Detected by Depth Electrocorticography During Clinical Multimodal Neuromonitoring
Neuro Trauma and Critical Care
P8 - Poster Session 8 (11:45 AM-12:45 PM)
18-004

To determine the incidence of spreading depolarizations (SD) detected using clinical depth electrocorticography (dECOG) in severe traumatic brain injury (sTBI).

SD are a signature pathomechanism of secondary brain injury and occur commonly after sTBI. The gold standard for recording SD involves operative placement of a strip electrode. Bedside multimodality neuromonitoring (MNM) strategies include dECOG in patients who do not undergo craniectomy. The incidence of SD detected by dECOG has not been reported.

A retrospective review of patients with sTBI undergoing MNM, including dECOG, over a 6-year period. Patients with or without contralateral hemicraniectomy and/or strip ECOG were included. The incidence of SD was quantified along with relationships to 3-6 month functional outcome.

There were n=160 patients monitored with dECOG; 5 had uninterpretable recordings. Patients were 41+/-18 years of age and 124 (80%) were male. Hemicraniectomy was performed in 70 patients (45%); a strip electrode was placed in 23/74 (35%).  Patients were monitored a median of 82 hours (interquartile range 58-124 hours). SD were detected by dECOG in 21/155 (14%) and Sz in 10/155 (6.5%). Of those with strip ECOG, SD were recorded in 16/23 (70%) and Sz in 5/23 (22%). Of patients with dECOG SD, 14/21 (67%) died or remained in a state of unresponsive wakefulness vs 53/134 patients without SD (40%; p=0.04). While numbers were limited, those with strip SD similarly exhibited worse outcome (10/16 [63%] of those with strip SD vs 2/7 [29%] without strip SD).

SD were detected using dECOG in 14% of patients undergoing multimodality neuromonitoring. Relative to strip ECOG monitoring, the lower incidence of SD using dECOG may reflect smaller spatial sampling and the lack of targeted peri-injury placement. However, the prognostic significance of SD detection remains similar, with worse functional outcome when SD are detected in either dECOG or strip ECOG.

Authors/Disclosures
Brandon P. Foreman, MD (University of Cincinnati)
PRESENTER
Dr. Foreman has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB Pharma Inc. Dr. Foreman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell, Inc. Dr. Foreman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sage Therapeutics. Dr. Foreman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Marinus Pharmaceuticals. Dr. Foreman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB Pharma Inc.. The institution of Dr. Foreman has received research support from DOD/AMRMC. The institution of Dr. Foreman has received research support from Biogen, Inc.. The institution of Dr. Foreman has received research support from DOD/AFRL. The institution of Dr. Foreman has received research support from NSF SCH:INT. The institution of Dr. Foreman has received research support from NIH/NIBIB. The institution of Dr. Foreman has received research support from DOD/JWMRP. The institution of Dr. Foreman has received research support from Marinus Pharmaceuticals. Dr. Foreman has received personal compensation in the range of $500-$4,999 for serving as a Honoraria with Natus Medical Incorporated. Dr. Foreman has received personal compensation in the range of $500-$4,999 for serving as a Honoraria with Ceribell, Inc.. Dr. Foreman has received personal compensation in the range of $0-$499 for serving as a Peer-to-peer program honoraria with Marinus Pharmaceuticals.
Davis L. Ewbank, DO Dr. Ewbank has nothing to disclose.
Gabrielle Dent Ms. Dent has nothing to disclose.
Rudy Luna, MD (Flats on the Row) Dr. Luna has nothing to disclose.
Brittany M. Kasturiarachi, DO Dr. Kasturiarachi has received personal compensation in the range of $500-$4,999 for serving as a Study Reviewer with EchoNous.
Laura B. Ngwenya, MD, PhD Dr. Ngwenya has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sophysa, USA. The institution of Dr. Ngwenya has received research support from NINDS/NIH. The institution of Dr. Ngwenya has received research support from Abbott.
Jed Hartings, PhD (University of Cincinnati) Dr. Hartings has nothing to disclose.